Jyong Biotech Ltd. (MENS:NASDAQ) closed at $1.89 on October 21, 2026, up 1.61% on the day. The stock trades 97.0% below its 52-week high of $63.00 and 32.2% above its 52-week low of $1.43. Over the past year, it lost 96.9%. Jyong Biotech Ltd. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, MENS closed higher on 108 days (43%). Its best day was December 30, 2025 (+51.80%) and its worst was December 17, 2025 (-81.04%). The stock moved 10% or more in a single session 35 times.
Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan. Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.
Find more stocks like MENS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.